Core Insights - The 2026 JPM conference showcased a positive outlook for Chinese innovative pharmaceutical companies, with significant interest from multinational corporations in collaboration opportunities [2][3][4] - Chinese companies are shifting from merely licensing patents to deeper involvement in clinical development and commercialization in international markets [3][8] - The FDA's stance at JPM was relatively moderate, acknowledging the R&D efficiency of Chinese companies and suggesting improvements in approval processes using AI [3][6] Group 1: Conference Overview - The JPM conference, held in San Francisco, attracted numerous founders, executives, and investors from Chinese innovative pharmaceutical companies, indicating a vibrant atmosphere compared to previous years [2][5] - The event has evolved from a small gathering to a major industry benchmark, with participation from nearly all multinational pharmaceutical companies [5][10] - The number of attendees increased significantly in 2026, reflecting a more optimistic market sentiment compared to the previous year [5][10] Group 2: Market Trends - The Chinese innovative drug sector experienced a substantial stock price increase from March to August 2025, driven by business development (BD) transactions and foreign capital inflow, but faced a market correction afterward [4][11] - The interest in Chinese assets is growing, with many multinational companies expressing intentions for mergers and acquisitions (M&A) and BD transactions [11][12] - The trend of Chinese companies seeking deeper engagement in global markets is evident, moving beyond simple patent licensing to collaborative operational models [8][9] Group 3: Regulatory Environment - FDA officials at JPM highlighted the efficiency of Chinese clinical trials, with China completing Phase I trials in four weeks compared to much longer timelines in the U.S. [6][12] - The FDA's comments suggested a focus on optimizing clinical trial approval processes rather than emphasizing protectionist policies [5][6] Group 4: Future Outlook - The absence of major transactions at JPM 2026 was noted, but many multinational companies expressed a willingness to explore significant deals in the near future [11][12] - The upcoming expiration of patents for several blockbuster drugs is expected to drive increased M&A activity as companies seek to replenish their pipelines [12][13] - The trend of U.S. biotech firms considering establishing operations in China to leverage R&D efficiencies is emerging, indicating a shift in cross-border collaboration dynamics [10][11]

本文字数：3320，阅读时长大约5分钟 作者 |第一财经 彭海斌 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿美 元。 2025年是中国创新药海外交易的大年。第一财经采访的医药和投资机构人士均认为，这种趋势会延续下 去。摩根大通大中华区医疗健康行业研究主管黄旸表示："2026年出海交易数量或者总金额可能难以超 过2025年，但会维持强劲的势头。" 首付款超过一级市场融资 2025年1月，先为达与英国企业Verdiva Bio Limited达成合作。 先为达是一家开发糖尿病及减重药物的中国企业。它将正在临床阶段的口服伊诺格鲁肽等授予后者大中 华区和韩国以外的开发权利。这笔交易的首付款约7000万美元，且可获得最高达24亿美元的潜在开发、 注册和商业化里程碑付款，以及产品商业化后的销售额提成。 2026.01.24 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，2025年中国新药对外授权交易158笔，总交易金额1357亿美元，交易数量和金额都达 到十年新高。 事实上，2023年和2024年， ...

Core Viewpoint - The trend of Chinese pharmaceutical companies expanding overseas continues to gain momentum, with significant transactions and collaborations expected to persist into 2026, although the total number and value of deals may not surpass those of 2025 [3][20]. Group 1: Overseas Authorization Transactions - In January 2026, Chinese pharmaceutical companies completed 10 overseas authorization transactions, with a notable deal between Rongchang Biopharma and AbbVie involving an upfront payment of $650 million [3]. - The year 2025 marked a record for overseas authorization transactions, with 158 deals totaling $135.7 billion, representing a ten-year high in both quantity and value [7]. - Major transactions in 2025 included a $12 billion strategic cooperation between Innovent Biologics and Takeda, and a $120 billion deal between Hengrui Medicine and GSK, contributing to a total upfront payment of $7 billion for Chinese innovative drugs [8]. Group 2: Market Dynamics and Trends - The U.S. remains the primary trading partner for Chinese pharmaceutical companies, accounting for approximately 48% of all overseas authorization transactions over the past decade [11]. - The increasing urgency for multinational pharmaceutical companies to replenish their pipelines due to impending patent expirations has led to heightened interest in Chinese biotech innovations [11][20]. - China's clinical trial efficiency is significantly higher than that of the U.S., with an average patient enrollment cost of $25,000 compared to $70,000 in the U.S., and a faster enrollment rate [15]. Group 3: Future Outlook - The momentum in overseas transactions is expected to continue, with companies increasingly recognizing the value of Chinese-developed drugs [18][20]. - Despite geopolitical tensions, collaboration between Chinese and U.S. pharmaceutical companies is strengthening, driven by mutual benefits in drug development [20]. - The Chinese pharmaceutical industry is establishing a competitive edge in innovation, although achieving global leadership akin to that in solar energy or automotive sectors may take more time and patience due to the complexities of drug development [20].

"这个势头是可持续的，并不会迅速开始下降。" 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿美元。 2025年是中国创新药海外交易的大年。第一财经采访的医药和投资机构人士均认为，这种趋势会延续下去。摩根大通大中华区医疗健康行业研究主管黄旸表 示："2026年出海交易数量或者总金额可能难以超过2025年，但会维持强劲的势头。" 首付款超过一级市场融资 最近两年，代谢领域的授权交易升温。2025年，中国药企发生了七笔对外授权。这很大程度上源于礼来和诺和诺德在减重药物市场取得的令人瞩目的成功。 礼来更是成为全球首家市值突破一万亿美元的医药公司，与英伟达、苹果、谷歌等科技巨头并肩而立。 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，2025年中国新药对外授权交易158笔，总交易金额1357亿美元，交易数量和金额都达到十年新高。 事实上，2023年和2024年，中国创新药海外授权交易的数量和交易额已经连续突破纪录。医药研发是厚积薄发的过程，即便是临床一期药物，也可能已经经 历了五年左右的研发。2025 ...

Group 1 - The active equity fund management scale decreased slightly in Q4 2025, primarily due to significant redemption pressure from existing funds, resulting in a net redemption of 165.6 billion yuan [1] - The total management scale of three types of active equity funds (ordinary stock, mixed equity, and flexible allocation) decreased by 189.8 billion yuan, with new active equity fund issuance at 56.2 billion yuan [1] - The active equity fund's position in Q4 2025 decreased by 0.83 percentage points to 86.62%, remaining at the second-highest level in history [2] Group 2 - In terms of sector allocation, the proportion of the ChiNext board increased by 1.24 percentage points to 24.98%, while the main board and Sci-Tech Innovation board saw declines [5][8] - The allocation to the main board decreased by 0.30 percentage points to 58.21%, indicating a further increase in underweight [8] - Active equity funds increased their positions in cyclical and financial real estate sectors while reducing exposure to technology growth and pharmaceuticals [11] Group 3 - The active equity funds increased their allocation in the non-ferrous metals, communication, and non-bank financial sectors, with increases of 2.26 percentage points, 1.85 percentage points, and 0.87 percentage points respectively [13] - The funds reduced their positions in electronics, pharmaceuticals, media, power equipment, and computers, with reductions of 1.72 percentage points, 1.54 percentage points, and 1.16 percentage points respectively [13] - Excluding thematic/sector funds, the active equity funds still increased their positions in non-ferrous metals, communication, and non-bank financial sectors [14] Group 4 - The allocation to the TMT sector slightly decreased in Q4 2025, with the configuration coefficient at 1.48, indicating room for further improvement [29] - Within the TMT sector, active equity funds increased their holdings in communication equipment and components while reducing positions in consumer electronics and semiconductors [32] - The dividend sector's allocation stabilized and increased, with the low-volatility dividend index rising by 1.7 percentage points to 4.3% [37] Group 5 - The top five stocks in active equity funds in Q4 2025 included Zhongji Xuchuang, Xinyi Sheng, Dongshan Precision, China Ping An, and Zijin Mining, with respective increases in holding ratios [43] - The top ten holdings accounted for 4.83%, 4.01%, and 3.97% of the total market value of the funds [46] - The concentration of individual stocks in active equity funds increased slightly, while the concentration of industries showed a mixed trend [49] Group 6 - The Hong Kong stock allocation of active equity funds decreased to 15.98%, down from 19.09%, with a total holding value of 302.9 billion yuan [51] - The funds increased their positions in the healthcare, materials, and energy sectors while reducing exposure to consumer discretionary and information technology sectors [54] - Tencent maintained its position as the largest holding in Hong Kong stocks, with a market value of 57.3 billion yuan [56]

Market Performance - After a six-day decline, the Hong Kong Stock Connect Innovation Drug ETF (520880) rebounded on January 23, rising over 2% at one point and closing up 1.53% with a trading volume of 348 million yuan [1][7] - Key constituent stocks such as Cloudtop New Drug led the gain with an 8.2% increase, while major stocks like Kangfang Biotech and CSPC Pharmaceutical rose by 3.5% [1][7] Policy Developments - On January 22, the Ministry of Commerce and nine other departments issued a document promoting high-quality development in the pharmaceutical retail industry, encouraging innovative drugs and reference preparations to enter retail pharmacy sales channels [3][9] - This policy is expected to provide a pathway for high-value innovative drugs, such as CAR-T, to fill the insurance coverage gap through commercial insurance directories [3][9] - The insurance industry association estimates that by 2025, the total compensation amount for innovative drugs and devices from commercial health insurance will reach approximately 14.7 billion yuan, with a compound annual growth rate of 70% over four consecutive years [3][9] Industry Insights - At the recent JPM conference, Chinese pharmaceutical companies showcased technological breakthroughs in areas such as ADC, IO dual antibodies, and GLP-1, moving towards global markets through licensing and collaborative development [3][9] - According to CITIC Securities, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation effectiveness [3][9] Investment Opportunities - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted as a high-elasticity T+0 investment tool, with its index (Hang Seng Hong Kong Stock Connect Innovation Drug Select Index) offering three unique advantages: 1. Purely innovative drugs with 100% purity, covering companies focused on innovative drug R&D [5][11] 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5][11] 3. Enhanced risk control through forced de-weighting of less liquid constituent stocks [5][11] Constituent Stocks - The top ten constituent stocks of the Hong Kong Stock Connect Innovation Drug ETF (520880) have a combined weight of 73.41%, showcasing a strong representation of leading companies in the innovative drug sector [6][12] - Notable constituents include: - Kangfang Biotech: 10.49% weight, market cap of 110.9 billion HKD - BeiGene: 10.01% weight, market cap of 312 billion HKD - CSPC Pharmaceutical: 9.97% weight, market cap of 102.1 billion HKD [6][12]

Group 1 - The stock position of actively managed equity funds decreased, while the A-share position continued to rise, with a total stock value of 3.39 trillion yuan at the end of Q4 2025, down by 0.19 trillion yuan from Q3 2025. The A-share market value was 2.91 trillion yuan, a decrease of 0.08 trillion yuan [2][8] - The stock allocation structure saw a decrease of 1.40 percentage points to 84.22%, remaining at a historically high level since 2005. The proportion of A-shares in asset allocation continued to rise, increasing by 0.66 percentage points to 72.18% [2][8] Group 2 - In Q4 2025, the allocation ratio for the ChiNext board increased from 23.62% to 24.83%, while the allocation ratios for other boards declined, with the Sci-Tech Innovation board down by 0.93 percentage points [12][13] - The large-cap style's holding value ratio increased by 1.24 percentage points, while the small-cap style decreased by 0.38 percentage points. Among the five major style indices, the cyclical style's holding value ratio rose by 3.23 percentage points [14][16] Group 3 - In terms of industry allocation, 18 primary industries saw an increase in holding value ratios, with notable increases in non-ferrous metals, communication, non-bank financials, basic chemicals, and machinery equipment, each rising by over 0.5 percentage points [17][20] - The top ten industries with increased holdings included communication equipment, industrial metals, insurance II, components, energy metals, general equipment, chemical products, minor metals, airport operations, and grid equipment [31][32] Group 4 - In the Hong Kong stock market, the allocation ratio for actively managed equity funds decreased to 16.10%, down by 3.09 percentage points from Q3 2025. The materials sector saw a significant increase in holding value ratio by 2.42 percentage points, while the financial sector increased by 2.33 percentage points [40][42] - The top five industries in the Hong Kong stock market included software services, medical biology, consumer discretionary retail, semiconductors, and non-ferrous metals, with respective holding values of 626 billion yuan, 430 billion yuan, 344 billion yuan, 237 billion yuan, and 213 billion yuan [45][46] Group 5 - The concentration of the top twenty stocks held by actively managed equity funds showed slight fluctuations, with 17 A-shares and 3 Hong Kong stocks. The number of stocks in the electronic and non-bank financial sectors increased by one, while those in the electric power equipment and medical biology sectors decreased by one [50][51]

Core Viewpoint - The market is experiencing significant differentiation as of Q4 2025, with a focus on the balance between returns, cycles, and risks rather than just the correctness of investment directions [1] Group 1: Fund Manager Insights - Fund manager Yao Zhipeng has been with Harvest Fund since 2011, focusing on growth and industry directions, and has extensive experience managing various product types [1][2] - The total scale of products managed by Yao Zhipeng is approximately 20 billion yuan, with Harvest Power Pioneer being a representative product [2] Group 2: Portfolio Composition - The top ten holdings of Harvest Power Pioneer include Ningde Times, Xinda Bio, Hunan Youneng, WuXi AppTec, O-film Tech, Zhongkuang Resources, Putailai, Nongfu Spring, Tianqi Lithium, and Xiaopeng Motors, indicating a multi-line structure [2][3] - The portfolio is built on three clear lines: 1. New energy, lithium battery, and new energy vehicle industry chain [3] 2. Pharmaceutical and innovative assets, reflecting ongoing attention to the innovative drug industry chain [3] 3. Consumer goods, with Nongfu Spring being one of the few hundred billion-level products in the food and beverage sector [4] Group 3: Market Environment Analysis - The overall market in Q4 2025 is characterized by a steady rise, with good returns in commercial aerospace, copper and aluminum commodities, chemicals, communications, and insurance, while cyclical assets have adjusted [4][5] - Yao Zhipeng expresses a cautious and neutral stance on the technology sector, highlighting the crowded nature of tech investments and the reevaluation of risks associated with AI [5][6] Group 4: Economic Outlook and Investment Strategy - The primary task for the Chinese economy in 2026 is to expand domestic demand, which will likely influence investment directions [6][7] - Long-term favored directions include new energy, new technology, new consumption, and innovative drugs, focusing on lithium batteries, embodied intelligent applications, and consumer assets that align with improving consumption [7] - Attention is also drawn to the potential for foreign capital inflow due to the appreciation of the RMB and the attractiveness of leading companies in various industries [8][9] Group 5: Portfolio Adjustment Strategy - Yao Zhipeng plans to gradually increase allocations to domestic demand and cyclical leading assets, enhancing the balance of the portfolio while dynamically adjusting based on macro and mid-level environmental changes [8][9]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a transaction volume exceeding 700 million yuan in a short period [1] - The ETF has seen a cumulative net inflow of over 430 million yuan in the past five days, with its latest scale surpassing 25.1 billion yuan, leading in its category [1] - The majority of the weighted stocks in the ETF's index have shown positive performance, including Kangfang Biopharma and Kelun-Botai, which both rose over 4% [3][4] Group 2 - Kangfang Biopharma announced that its new humanized anti-IL-17A monoclonal antibody, AK111, has received acceptance for a new drug application for treating active ankylosing spondylitis (AS) by the National Medical Products Administration (NMPA) [3] - This new drug is expected to provide a new treatment option for nearly 4 million AS patients in China [3] - The JPMorgan Healthcare Conference highlighted the achievements of Chinese innovative drug companies, with expectations for significant revenue growth and multiple drug approvals in the coming years [5][6] Group 3 - The domestic pharmaceutical industry is witnessing rapid technological advancements and an acceleration in globalization, with significant transactions exceeding 10 billion USD occurring [6][7] - The industry is entering a critical period of validation for innovative drug performance, with many companies expected to launch global registration studies and new product applications [6][7] - A domestic innovative drug company projected a revenue increase of 15.84% for 2025, with a substantial net profit growth of 102.65% [7]

1月23日早盘，港股通创新药板块强势反弹，高弹性港股通创新药ETF（520880）急速冲上2%！成份股 方面，云顶新耀、映恩生物-B领衔涨势，权重股康方生物涨超5%。 消息面，1月22日，商务部联合国家发展改革委、国家医保局等9部门印发《关于促进药品零售行业高质 量发展的意见》，明确提出鼓励创新药、参比制剂等进入零售药店销售渠道，并推动电子处方流转平台 建设，支持实体医疗机构与互联网医院与零售药店对接，优化购药体验。 分析人士指出，该政策旨在强化药品零售端的专业服务功能，提升创新药可及性，尤其为高值创新药 （如CAR-T）通过商保目录补充医保保障缺口提供落地路径。 二级市场资金提前埋伏，此前港股通创新药板块连阴6日，资金频频借道港股通创新药ETF（520880） 逢跌吸筹。数据显示，本周以来，520880累计获超2.3亿元资金净申购，最新份额升至45.38亿份，续创 历史新高！ 一键投资创新药，认准高弹性T+0利器——港股通创新药ETF（520880）及其场外联接基金 （025221），其跟踪的恒生港股通创新药精选指数具备三大独特优势，配置价值突出： 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发 ...